Castration-Resistant Prostate Cancer (CRPC)
Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.
... suppressor cells (MDSCs) in metastatic castration-resistant prostate cancer (CRPC) patients 20. (PTS)[r] ...
23
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
... Prostate Cancer (PCa) is an important age-related disease being the most common cancer malignancy and the second leading cause of cancer mortality in men in Western ...of Castration- ...
14
Molecular profiling of peripheral blood is associated with circulating tumor cells content and poor survival in metastatic castration-resistant prostate cancer
... in castration-resistant prostate cancer ...metastatic CRPC patients with known CTC content in order to identify genes that may be related to prostate cancer ...in ...
13
Exponential Rise in Prostate Specific Antigen (PSA) during Anti Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration Resistant Prostate Cancer
... of prostate-specific antigen (PSA) before chemotherapy and PSA flare during the early phase of chemo- therapy in patients with castration-resistant prostate cancer ...with CRPC ...
7
Switching of GnRH Agent from Agonist to Antagonist in Patients with Castration Resistant Prostate Cancer
... with castration-resistant prostate cancer ...with CRPC were switched from GnRH agonist to GnRH antagonist. CRPC was defined as 3 consecutive rises of PSA values under androgen ...
10
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
... advanced prostate cancer initially respond to androgen deprivation therapy (ADT), but inevitably relapse with fatal castration-resistant prostate cancer (CRPC); there is ...
10
The 2015 CUA CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC)
... Castration-resistant prostate cancer (CRPC) is defined by disease progression despite castrate levels of testosterone and may present as either a continuous rise in serum pros- ...
7
Monitoring dynamic cytotoxic chemotherapy response in castration resistant prostate cancer using plasma cell free DNA (cfDNA)
... Results: Peripheral blood was obtained from 15 patients with metastatic castration-resistant prostate cancer (CRPC) immediately before and after cytotoxic chemotherapy infusion. cfDNA ...
7
Prognostic and predictive clinical factors in patients with metastatic castration resistant prostate cancer treated with cabazitaxel
... Prostate cancer is the most commonly diagnosed cancer in men and the third leading cause of cancer-related death in men in Canada and the United ...metastatic ...
17
Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer
... metastatic castration-resistant prostate cancer (mCRPC) provide latitude in designing treatment plans that meet patients’ medical needs and personal ...
8
CUA CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update
... time to first SRE (488 vs. 321 days, p = 0.01). There was an overall 36% reduction in the rate of SREs in treated patients. Zoledronic acid should be initiated at reduced dose in men with impaired renal function ...
7
LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models
... positive’ CRPC. CRPC driven through other AR activating mechanisms, such as activating point mutations, AR amplification, AR phosphorylation or AR methylation should be investi- gated ...
9
PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study
... (M0) CRPC and metastatic (M1) CRPC (mCRPC) were ...of Cancer Therapy questionnaire for patients with prostate cancer (FACT-P) and the FACT-General (FACT-G) ...
8
Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population
... of CRPC, patient age, category of age (40–54; 55–64; 65–74; 75 + ), insurance type (commercial or Medicare Advantage), and geographic census region in which the patient was enrolled in a health plan (Northeast, ...
13
Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience
... of prostate-specific antigen (PSA) response ( ≥ 50 % drop of PSA from baseline) within the first 3 months of therapy was associated with favorable OS and PFS in both chemo-naive and post-chemo ...
10
Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer
... CRPC: castration-resistant prostate cancer; TME: tumor microenvironment; AR: androgen receptor; AR-V7: androgen receptor splice variant 7; ADT: androgen deprivation therapy; PSA: ...
10
Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
... of prostate cancer is a cornerstone to our understanding of the molecular mechanisms causing castration-resistant prostate cancer ...advanced prostate cancer to ...
8
Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21 Cip1 and p27 Kip1
... Prostate cancer is the second most frequently diagnosed cancer of men and the fifth most common cancer overall in the ...of prostate cancer (PCa) is increasing steadily in almost ...
24
DNA vaccination for prostate cancer: key concepts and considerations
... cell; CRPC: Castration resistant prostate cancer; CTLs: Cytotoxic T lymphocytes; DNA: Deoxyribonucleic acid; DOM: Domain of fragment C tetanus toxin; DTH: Delayed-type hypersensitivity; ...
23
Evaluation and consequences of heterogeneity in the circulating tumor cell compartment
... colorectal cancer; CRPC, castration resistant prostate cancer; CTC, circulating tumor cell; DGE, digital gene extraction; EMT, epithelial‑to‑mesenchymal transition; FISH, ...
19